Study how gut chemicals and alcohol affect heart risk in HIV
Part of Ear, nose & throat, Genetic & congenital, Heart & circulation, Immune system & allergy, Infections clinical trials.
This Phase 2 study looks at how “microbiome metabolites” (chemicals from gut bacteria) and alcohol may affect heart and blood vessel risk in people living with HIV. If you qualify, you may be asked to follow a study plan to see how these factors change health markers related to cardiovascular disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a diagnosis of HIV.
- You must be able to participate in the study in English (be fluent).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a special microbiome treatment can help reduce alcohol-related harm in people with HIV. You may be eligible if you have HIV and have been drinking alcohol recently.
This study looks at how changing your HIV medication affects the bacteria in your gut. You'll provide two stool samples so researchers can see what changes happen.
This study looks at how aging affects heart health in people who have HIV. It may help researchers find better ways to prevent or monitor heart problems over time.
This study looks at how alcohol use affects people with HIV who take multiple medications, including certain brain or nerve drugs. It aims to find safer ways to manage their health.
This study looks back at people with HIV to understand how often and why heart problems happen. It may help doctors better track heart risk and complications over time.
This trial studies how the bacteria in your gut (“microbiome”) relate to frailty (weakness/low physical resilience) in people with HIV who are stably doing well on treatment. It may help researchers understand why some people become frail and how the gut may play a role.
Hear when a new Microtia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.